IBD-RESPONSE is a UK-wide multi-centre observational cohort study that will develop a predictive algorithm for response or failure to respond to biologic, janus kinase inhibitor (JAKi) and sphingosine-1-phosphate receptor (S1PR) modulator therapies in Crohn's disease and ulcerative colitis.
Launched in 2022 our precision medicine research will follow 1,325 patients for the first year after commencing one of these therapies.
We will utilise multiple cutting edge technologies to study the gut microbiome, the human genome and immune system integrated with clinical outcome data utilising machine learning techniques.
Click on the image to watch our video and find out more
Meet the team of clinicians and scientists that are working hard to set up IBD-RESPONSE at 40 centres across the UK
IBD-RESPONSE may shape how clinicians and patients tailor individual treatment choices for IBD in the future
Read more about CD-metaRESPONSE and how it differs to and complements IBD-RESPONSE
Check below to see a summary of our published work within IBD-RESPONSE